{"id":749518,"date":"2023-04-20T08:35:28","date_gmt":"2023-04-20T12:35:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/"},"modified":"2023-04-20T08:35:28","modified_gmt":"2023-04-20T12:35:28","slug":"acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/","title":{"rendered":"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results"},"content":{"rendered":"
\n

CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (\u201cAcutus\u201d or the \u201cCompany\u201d) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to the release of the RECOVER AF study data (published online in EP Europace<\/em>)1<\/sup>.<\/em><\/p>\n

\n Preliminary Unaudited First Quarter 2023 Results<\/strong>
\n
The Company expects first quarter 2023 revenue in the range of $4.1-$4.2 million compared to $3.7 million in the first quarter of 2022. Year-over-year growth was driven by higher AcQMap\u2122 disposable revenue in markets outside the United States, increased Service and Other Revenue, and sales through the Company\u2019s distribution agreement with Medtronic. As expected, the Company\u2019s results for the first quarter of 2023 were adversely impacted by supply chain shortages that are expected to be resolved in the balance of the year. Excluding the cash proceeds from Sale of Business and ERC Credit, cash burn is expected to decline on a year-over-year basis by approximately 35%, reflecting ongoing cost savings, partially offset by inventory replenishment to support current and future expected demand.<\/p>\n

\u201cWe are pleased with the overall performance of our business in the first quarter, despite ongoing supply chain challenges and a constrained hospital capex spending environment. While we had a slow start in terms of AcQMap cases, we saw a progressive increase in procedure volume by quarter end,\u201d said David Roman, President & CEO of Acutus. \u201cThe recently published RECOVER AF study data demonstrate the profound impact we have on patient care, and we believe AcQMap\u2019s proven capability to personalize ablation therapy and improve outcomes sets the business up for growth in 2023 and beyond.\u201d<\/p>\n

The preliminary unaudited revenue results described in this press release are estimates only and are subject to revision until we report our full financial results for the first quarter of 2023 on Thursday, May 11, 2023.<\/p>\n

References:<\/p>\n

    \n
  1. Betts et al. Treatment of pathophysiologic propagation outside of the pulmonary veins in retreatment of atrial fibrillation patients: Recover AF study. Europace. 2023. doi:10.1093\/europace\/euad097<\/li>\n<\/ol>\n

    \n About Acutus Medical, Inc.<\/strong>
    \n
    Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.<\/p>\n

    \n Caution Regarding Forward-Looking Statements<\/strong>
    \n
    This press release includes statements that may constitute \u201cforward-looking\u201d statements, usually containing the words \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cexpect\u201d or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company\u2019s ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of its products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase the Company\u2019s systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally, including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the impact of the coronavirus (COVID-19) pandemic and Acutus\u2019 response to it, and other risks discussed in the Company\u2019s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.<\/p>\n

    \n Follow Acutus Medical on: <\/strong>
    \n Twitter<\/a>, LinkedIn<\/a>, YouTube<\/a> and Facebook<\/a>.<\/p>\n

    \n Investor Contact<\/strong>
    \n
    Caroline Corner
    415-202-5678
    caroline.corner@westwicke.com<\/a><\/p>\n

    \n Media Contact<\/strong>
    \n
    Rhiannon Pickus
    442-232-6094
    Rhiannon.Pickus@acutus.com<\/a><\/p>\n

    \n
    \n
    \n \n <\/div>\n

    <\/div>\n","protected":false},"excerpt":{"rendered":"

    CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (\u201cAcutus\u201d or the \u201cCompany\u201d) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to the release of the RECOVER AF study data (published online in EP Europace)1. Preliminary Unaudited First Quarter 2023 Results The Company expects first quarter 2023 revenue in the range of $4.1-$4.2 million compared to $3.7 million in the first quarter of 2022. Year-over-year growth was driven by higher AcQMap\u2122 disposable revenue in markets outside the United States, increased Service and Other Revenue, and sales through the Company\u2019s distribution agreement with Medtronic. As expected, the Company\u2019s … <\/p>\n

    Continue reading “Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-749518","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAcutus Medical Announces Preliminary Unaudited First Quarter 2023 Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (\u201cAcutus\u201d or the \u201cCompany\u201d) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to the release of the RECOVER AF study data (published online in EP Europace)1. Preliminary Unaudited First Quarter 2023 Results The Company expects first quarter 2023 revenue in the range of $4.1-$4.2 million compared to $3.7 million in the first quarter of 2022. Year-over-year growth was driven by higher AcQMap\u2122 disposable revenue in markets outside the United States, increased Service and Other Revenue, and sales through the Company\u2019s distribution agreement with Medtronic. As expected, the Company\u2019s … Continue reading "Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-20T12:35:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results\",\"datePublished\":\"2023-04-20T12:35:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/\"},\"wordCount\":663,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/\",\"name\":\"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY=\",\"datePublished\":\"2023-04-20T12:35:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/","og_locale":"en_US","og_type":"article","og_title":"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results - Market Newsdesk","og_description":"CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (\u201cAcutus\u201d or the \u201cCompany\u201d) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to the release of the RECOVER AF study data (published online in EP Europace)1. Preliminary Unaudited First Quarter 2023 Results The Company expects first quarter 2023 revenue in the range of $4.1-$4.2 million compared to $3.7 million in the first quarter of 2022. Year-over-year growth was driven by higher AcQMap\u2122 disposable revenue in markets outside the United States, increased Service and Other Revenue, and sales through the Company\u2019s distribution agreement with Medtronic. As expected, the Company\u2019s … Continue reading \"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-20T12:35:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results","datePublished":"2023-04-20T12:35:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/"},"wordCount":663,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/","name":"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY=","datePublished":"2023-04-20T12:35:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMTg2OSM1NTM3MjYwIzIyMDAwNjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acutus-medical-announces-preliminary-unaudited-first-quarter-2023-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=749518"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749518\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=749518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=749518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=749518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}